Literature DB >> 16045745

Detection of in vitro interferon-gamma and serum tumour necrosis factor-alpha in multidrug-resistant tuberculosis patients.

A Fortes1, K Pereira, P R Z Antas, C L M C Franken, M Dalcolmo, M M Ribeiro-Carvalho, K S Cunha, A Geluk, A Kritski, A Kolk, P Klatser, E N Sarno, T H M Ottenhoff, E P Sampaio.   

Abstract

Multidrug-resistant tuberculosis (MDR-TB) is known as having a poor prognosis with a weak response to therapy and very high death rates. The aim of this work was to assess the immune response to the RD1-encoded antigen ESAT-6 of Mycobacterium tuberculosis in MDR-TB patients and compare to non-resistant (NR) TB patients and healthy controls (HC). Evaluation of interferon (IFN)-gamma production showed that, although 55% of the MDR patients were responsive to ESAT-6, they produced lower IFN-gamma levels (553 +/- 11 pg/ml) when compared to NR-TB (1179 +/- 163 pg/ml; P < 0.05) but not to controls (412 +/- 65.7 pg/ml). Differences in the response to ESAT-6 and to its overlapping peptides mixture were also significant between MDR versus treated pulmonary NR-TB. Furthermore, a very low rate of response to PPD (23.5%) and to Ag85B (33.3%) was noted in MDR-TB patients as compared to the other groups. To determine the inflammatory response in patients' groups, detection of tumour necrosis factor (TNF)-alpha was assessed in their sera before and during chemotherapy. Mean TNF-alpha levels in MDR-TB (43.8 +/- 9 pg/ml) paralleled those found in treated pulmonary, and it was significantly different (P < 0.05) from the values found in untreated NR and HC. Interestingly, secretion of IFN-gamma and TNF-alpha were predominant in MDR patients who presented with bilateral pulmonary lesions and lung cavitation. The present data indicate that the overall immune response to mycobacterial antigens is decreased in resistant TB and the major role inflammatory cytokines may play in perpetuating pulmonary tissue damage.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16045745      PMCID: PMC1809469          DOI: 10.1111/j.1365-2249.2005.02872.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  36 in total

1.  Dysregulated production of interferon-gamma, interleukin-4 and interleukin-6 in early tuberculosis patients in response to antigen 85B of Mycobacterium tuberculosis.

Authors:  E K Jo; H J Kim; J H Lim; D Min; Y Song; C H Song; T H Paik; J W Suhr; J K Park
Journal:  Scand J Immunol       Date:  2000-02       Impact factor: 3.487

2.  Criteria for the control of drug-resistant tuberculosis.

Authors:  C Dye; B G Williams
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-05       Impact factor: 11.205

3.  Detection of active tuberculosis infection by T cell responses to early-secreted antigenic target 6-kDa protein and culture filtrate protein 10.

Authors:  S M Arend; P Andersen; K E van Meijgaarden; R L Skjot; Y W Subronto; J T van Dissel; T H Ottenhoff
Journal:  J Infect Dis       Date:  2000-05-15       Impact factor: 5.226

4.  Increased numbers of ESAT-6- and purified protein derivative-specific gamma interferon-producing cells in subclinical and active tuberculosis infection.

Authors:  T Ulrichs; P Anding; S Porcelli; S H Kaufmann; M E Munk
Journal:  Infect Immun       Date:  2000-10       Impact factor: 3.441

5.  Tuberculosis and drug resistance among patients seen at an AIDS Reference Center in São Paulo, Brazil.

Authors:  W P Pinto; D J Hadad; M A Silva Telles; S Y Ueki; M Palaci; M A Basile
Journal:  Int J Infect Dis       Date:  2001       Impact factor: 3.623

6.  Tuberculosis contacts but not patients have higher gamma interferon responses to ESAT-6 than do community controls in The Gambia.

Authors:  J Vekemans; C Lienhardt; J S Sillah; J G Wheeler; G P Lahai; M T Doherty; T Corrah; P Andersen; K P McAdam; A Marchant
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

7.  Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent.

Authors:  J Keane; S Gershon; R P Wise; E Mirabile-Levens; J Kasznica; W D Schwieterman; J N Siegel; M M Braun
Journal:  N Engl J Med       Date:  2001-10-11       Impact factor: 91.245

8.  Enumeration of T cells specific for RD1-encoded antigens suggests a high prevalence of latent Mycobacterium tuberculosis infection in healthy urban Indians.

Authors:  A Lalvani; P Nagvenkar; Z Udwadia; A A Pathan; K A Wilkinson; J S Shastri; K Ewer; A V Hill; A Mehta; C Rodrigues
Journal:  J Infect Dis       Date:  2000-12-21       Impact factor: 5.226

9.  Depressed interleukin-12 (IL-12), but not IL-18, production in response to a 30- or 32-kilodalton mycobacterial antigen in patients with active pulmonary tuberculosis.

Authors:  C H Song; H J Kim; J K Park; J H Lim; U O Kim; J S Kim; T H Paik; K J Kim; J W Suhr; E K Jo
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

10.  Antigenic equivalence of human T-cell responses to Mycobacterium tuberculosis-specific RD1-encoded protein antigens ESAT-6 and culture filtrate protein 10 and to mixtures of synthetic peptides.

Authors:  S M Arend; A Geluk; K E van Meijgaarden; J T van Dissel; M Theisen; P Andersen; T H Ottenhoff
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

View more
  9 in total

Review 1.  The emergence of Beijing family genotypes of Mycobacterium tuberculosis and low-level protection by bacille Calmette-Guérin (BCG) vaccines: is there a link?

Authors:  F Abebe; G Bjune
Journal:  Clin Exp Immunol       Date:  2006-09       Impact factor: 4.330

2.  Different immunosuppressive mechanisms in multi-drug-resistant tuberculosis and non-tuberculous mycobacteria patients.

Authors:  R O Pinheiro; E B de Oliveira; G Dos Santos; G M Sperandio da Silva; B J de Andrade Silva; R M B Teles; A Milagres; E N Sarno; M P Dalcolmo; E P Sampaio
Journal:  Clin Exp Immunol       Date:  2013-02       Impact factor: 4.330

3.  Patients with multidrug-resistant tuberculosis display impaired Th1 responses and enhanced regulatory T-cell levels in response to an outbreak of multidrug-resistant Mycobacterium tuberculosis M and Ra strains.

Authors:  Laura Geffner; Noemí Yokobori; Juan Basile; Pablo Schierloh; Luciana Balboa; María Mercedes Romero; Viviana Ritacco; Marisa Vescovo; Pablo González Montaner; Beatriz Lopez; Lucía Barrera; Mercedes Alemán; Eduardo Abatte; María C Sasiain; Silvia de la Barrera
Journal:  Infect Immun       Date:  2009-08-31       Impact factor: 3.441

4.  Sex-Dependent Differential Expression of Lipidic Mediators Associated with Inflammation Resolution in Patients with Pulmonary Tuberculosis.

Authors:  Claudia Carranza; Laura Elena Carreto-Binaghi; Silvia Guzmán-Beltrán; Marcela Muñoz-Torrico; Martha Torres; Yolanda González; Esmeralda Juárez
Journal:  Biomolecules       Date:  2022-03-24

Review 5.  The impact of drug resistance on Mycobacterium tuberculosis physiology: what can we learn from rifampicin?

Authors:  Anastasia Koch; Valerie Mizrahi; Digby F Warner
Journal:  Emerg Microbes Infect       Date:  2014-03-12       Impact factor: 7.163

6.  A combination of baseline plasma immune markers can predict therapeutic response in multidrug resistant tuberculosis.

Authors:  Selena Ferrian; Claudia Manca; Sugnet Lubbe; Francesca Conradie; Nazir Ismail; Gilla Kaplan; Clive M Gray; Dorothy Fallows
Journal:  PLoS One       Date:  2017-05-02       Impact factor: 3.240

7.  Autologous Cytokine-Induced Killer Cell Immunotherapy Enhances Chemotherapy Efficacy against Multidrug-Resistant Tuberculosis.

Authors:  Peijun Tang; Xingnian Chen; Junchi Xu; Yunlong Hu; Zhijian Ye; Xiafang Wang; Yumei Xiao; Xinghua Shen; Jianping Zhang; Yanjun Feng; Cuilin Shi; Xin Yu; Lixian Yi; Xinchun Chen; Binfeng Lu; Ping Xu; Zhongwen Sun; Meiying Wu
Journal:  J Immunol Res       Date:  2022-03-17       Impact factor: 4.818

Review 8.  Therapeutic potential of interferon-gamma in tuberculosis.

Authors:  Svetlana A Berns; Julia A Isakova; Polina I Pekhtereva
Journal:  ADMET DMPK       Date:  2022-02-14

9.  Risk factors and clinical phenotypes of Beijing genotype strains in tuberculosis patients in China.

Authors:  Yu Pang; Yuanyuan Song; Hui Xia; Yang Zhou; Bing Zhao; Yanlin Zhao
Journal:  BMC Infect Dis       Date:  2012-12-17       Impact factor: 3.090

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.